Journal of International Oncology ›› 2020, Vol. 47 ›› Issue (12): 732-736.doi: 10.3760/cma.j.cn371439-20200419-00110
• Reviews • Previous Articles Next Articles
Received:
2020-04-19
Revised:
2020-05-18
Online:
2020-12-08
Published:
2021-01-28
Contact:
Shen Jianzhen
E-mail:doctorsjz@163.com
Supported by:
Liu Yanquan, Shen Jianzhen. Correlation between CXCR1 and malignant tumors[J]. Journal of International Oncology, 2020, 47(12): 732-736.
[1] |
Fu Q, Yang Y, Li C, et al. The chemokinome superfamily:Ⅱ. The 64 CC chemokines in channel catfish and their involvement in disease and hypoxia responses[J]. Dev Comp Immunol, 2017,73:97-108. DOI: 10.1016/j.dci.2017.03.012.
pmid: 28322933 |
[2] | Sakai H, Yabe S, Sato K, et al. ELR+ chemokine-mediated neutrophil recruitment is involved in 2,4,6-trinitrochlorobenzene-induced contact hypersensitivity[J]. Clin Exp Pharmacol Physiol, 2018,45(1):27-33. DOI: 10.1111/1440-1681.12839. |
[3] | Wang Y, Cecylia SL, Wang T, et al. A computational study of the chemokine receptor CXCR1 bound with interleukin-8[J]. Chin Phys B, 2018,27(3): 038702-1-038702-10. DOI: 10.1088/1674-1056/27/3/038702. |
[4] | Bishayi B, Adhikary R, Sultana S, et al. Altered expression of CXCR1 (IL-8R) in macrophages utilizing cell surface TNFR1 and IL-1 receptor during Staphylococcus aureus infection[J]. Microb Pathog, 2017,113:460-471. DOI: 10.1016/j.micpath.2017.11.028. |
[5] |
Ng YY, Tay JCK, Wang S. CXCR1 Expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts[J]. Mol Ther Oncolytics, 2019,16:75-85. DOI: 10.1016/j.omto.2019.12.006.
doi: 10.1016/j.omto.2019.12.006 pmid: 31970285 |
[6] | 毕惠娟, 陈建民, 陈静静, 等. 原发性肝癌患者CXCR1、CXCR2及CXCL8的表达及其临床意义[J]. 中华微生物学和免疫学杂志, 2017,37(7):545-551. DOI: 10.3760/cma.j.issn.0254-5101.2017.07.012. |
[7] |
Yu J, Ren X, Chen Y, et al. Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients[J]. PLoS One, 2013,8(2):e56069. DOI: 10.1371/journal.pone.0056069.
doi: 10.1371/journal.pone.0056069 pmid: 23418512 |
[8] | An Z, Li J, Yu J, et al. Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages[J]. Cell Cycle, 2019,18(21):2928-2938. DOI: 10.1080/15384101.2019.1662678. |
[9] | Bi H, Zhang Y, Wang S, et al. Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer[J]. Oncol Lett, 2019,18(4):4176-4184. DOI: 10.3892/ol.2019.10735. |
[10] |
Wang Z, Liu H, Shen Z, et al. The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients[J]. BMC Cancer, 2015,15:766. DOI: 10.1186/s12885-015-1793-9.
pmid: 26497045 |
[11] |
Jia X, Lu M, Rui C, et al. Consensus-expressed CXCL8 and MMP9 identified by meta-analyzed perineural invasion gene signature in gastric cancer microarray data[J]. Front Genet, 2019,10:851. DOI: 10.3389/fgene.2019.00851.
doi: 10.3389/fgene.2019.00851 pmid: 31681401 |
[12] | Chen X, Chen R, Jin R, et al. The role of CXCL chemokine family in the development and progression of gastric cancer[J]. Int J Clin Exp Pathol, 2020,13(3):484-492. |
[13] | 余亮, 周国强, 余生元, 等. 白细胞介素8及白细胞介素受体1信号轴在胃癌组织中的临床意义[J]. 中华老年医学杂志, 2018,37(4):427-430. DOI: 10.3760/cma.j.issn.0254-9026.2018.04.017. |
[14] |
Cao Y, Liu H, Zhang H, et al. CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM Ⅱ and Ⅲ resectable gastric cancer patients[J]. Oncotarget, 2017,8(12):20328-20339. DOI: 10.18632/oncotarget.12815.
pmid: 27780937 |
[15] | 姚小健, 黄红霞, 陈勇, 等. CXCR1调控STAT3信号通路对结肠癌细胞增殖凋亡的影响[J]. 医学研究杂志, 2017,46(8):126-131. DOI: 10.11969/j.issn.1673-548X.2017.08.031. |
[16] |
Fisher RC, Bellamkonda K, Alex Molina L, et al. Disrupting inflammation-associated CXCL8-CXCR1 signaling inhibits tumori-genicity initiated by sporadic- and colitis-colon cancer stem cells[J]. Neoplasia, 2019,21(3):269-281. DOI: 10.1016/j.neo.2018.12.007.
pmid: 30738331 |
[17] |
Zhu Y, Liu Z, Wang Y, et al. High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients[J]. Oncoimmunology, 2017,6(11):e1359450. DOI: 10.1080/2162402X.2017.1359450.
doi: 10.1080/2162402X.2017.1359450 |
[18] |
Corrò C, Healy ME, Engler S, et al. IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer[J]. J Pathol, 2019,248(3):377-389. DOI: 10.1002/path.5267.
doi: 10.1002/path.5267 pmid: 30883740 |
[19] |
Wu S, Saxena S, Varney ML, et al. CXCR1/2 chemokine network regulates melanoma resistance to chemotherapies mediated by NF-κB[J]. Curr Mol Med, 2017,17(6):436-449. DOI: 10.2174/1566524018666171219100158.
doi: 10.2174/1566524018666171219100158 pmid: 29256349 |
[20] |
Kemp DM, Pidich A, Larijani M, et al. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment[J]. Oncotarget, 2017,8(9):14428-14442. DOI: 10.18632/oncotarget.14803.
doi: 10.18632/oncotarget.14803 pmid: 28129639 |
[21] | Uen WC, Hsieh CH, Tseng TT, et al. Anchorage independency promoted tumor malignancy of melanoma cells under reattachment through elevated interleukin-8 and CXC chemokine receptor 1 expression[J]. Melanoma Res, 2015,25(1):35-46. DOI: 10.1097/CMR.0000000000000134. |
[22] | BeLow M, Osipo C. Notch signaling in breast cancer: a role in drug resistance[J]. Cells, 2020,9(10):2204. DOI: 10.3390/cells9102204. |
[23] | Wang X, Semba T, Phi LTH, et al. Targeting signaling pathways in inflammatory breast cancer[J]. Cancers (Basel), 2020,12(9):2479. DOI: 10.3390/cancers12092479. |
[24] | Wang RX, Ji P, Gong Y, et al. Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study[J]. Breast Cancer Res Treat, 2020,181(3):561-570. DOI: 10.1007/s10549-020-05660-z. |
[25] |
Xue MQ, Liu J, Sang JF, et al. Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer[J]. Oncotarget, 2017,8(30):48930-48937. DOI: 10.18632/oncotarget.16893.
doi: 10.18632/oncotarget.16893 pmid: 28454081 |
[26] |
Khurram SA, Bingle L, McCabe BM, et al. The chemokine receptors CXCR1 and CXCR2 regulate oral cancer cell behaviour[J]. J Oral Pathol Med, 2014,43(9):667-674. DOI: 10.1111/jop.12191.
doi: 10.1111/jop.12191 pmid: 24965032 |
[27] |
Spaks A. Role of CXC group chemokines in lung cancer development and progression[J]. J Thorac Dis, 2017,9(Suppl 3):S164-S171. DOI: 10.21037/jtd.2017.03.61.
doi: 10.21037/jtd.2017.03.61 pmid: 28446981 |
[28] | Han XG, Yang SB, Mo HM, et al. Targeting of CXCR1 on osteosarcoma circulating tumor cells and precise treatment via cisplatin nanodelivery[J]. Adv Fun Mater, 2019,29(34):1902246. DOI: 10.1002/adfm.201902246. |
[29] |
Wang J, Hu W, Wang K, et al. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil[J]. Int J Oncol, 2016,48(4):1341-1352. DOI: 10.3892/ijo.2016.3371.
doi: 10.3892/ijo.2016.3371 pmid: 26847910 |
[30] |
Shang FM, Li J. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway[J]. Med Clin (Barc), 2019,152(11):425-430. DOI: 10.1016/j.medcle.2018.08.016.
doi: 10.1016/j.medcli.2018.08.006 |
[31] |
Liu X, Peng J, Sun W, et al. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice[J]. Tohoku J Exp Med, 2012,228(2):147-156. DOI: 10.1620/tjem.228.147.
doi: 10.1620/tjem.228.147 |
[32] |
Goldstein LJ, Perez RP, Yardley D, et al. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer[J]. Breast Cancer Res, 2020,22(1):4. DOI: 10.1186/s13058-019-1243-8.
doi: 10.1186/s13058-019-1243-8 pmid: 31924241 |
[33] |
Li X, Zhang Y, Walana W, et al. GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer[J]. Future Oncol, 2020,16(14):911-921. DOI: 10.2217/fon-2020-0035.
doi: 10.2217/fon-2020-0035 pmid: 32285685 |
[34] |
Susek KH, Karvouni M, Alici E, et al. The role of CXC chemokine receptors 1-4 on immune cells in the tumor microenvironment[J]. Front Immunol, 2018,9:2159. DOI: 10.3389/fimmu.2018.02159.
doi: 10.3389/fimmu.2018.02159 pmid: 30319622 |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[5] | Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353. |
[6] | Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[7] | Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[8] | Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[9] | Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[10] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[11] | Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[12] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[13] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[14] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[15] | Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||